1,146 results on '"Brice, Pauline"'
Search Results
2. Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group
3. Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up
4. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
5. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study
6. Procarbazine-induced Genomic Toxicity in Hodgkin Lymphoma Survivors
7. Classical Hodgkin lymphoma
8. Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials
9. Hepatitis B virus-associated B-cell non-Hodgkin lymphoma in non-endemic areas in Western Europe: Clinical characteristics and prognosis
10. Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study
11. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
12. Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation
13. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study
14. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
15. L’arrivée de l’immunothérapie dans le lymphome de Hodgkin
16. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts
17. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial
18. Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients
19. Skin involvement in systemic lymphoma of follicular helper T-cell origin: a cohort study of 57 patients
20. P1166: BRIGATINIB IN PATIENTS WITH ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA WHO HAVE FAILED BRENTUXIMAB VEDOTIN
21. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma
22. ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)–Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial
23. Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients
24. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma
25. Lymphomes hodgkiniens et non hodgkiniens des adolescents et des jeunes adultes
26. Skin involvement in systemic lymphoma of follicular helper T‐cell origin: A cohort study of 57 patients.
27. Supplemental Figures 1-8 from The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association
28. O-129 - Skin involvement in systemic lymphoma of follicular helper T-cell origin: a cohort study of 57 patients
29. 18F-fluorodeoxyglucose-positron emission tomography is more sensitive than computed tomography in initial staging of patients with an anaplastic T-cell lymphoma first presenting in the skin
30. Immediate hypersensitivity reaction to pegylated liposomal doxorubicin: management and outcome in four patients
31. Analyses of patterns-of-failure and prognostic factors according to radiation fields in early-stage Hodgkin lymphoma
32. High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO 16 LYMPHOVIR Cohort
33. Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA
34. Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy
35. Should Adolescents and Young Adults with Hodgkin Lymphoma be Treated As Children or Adults?
36. P109: One-Day Brentuximab-Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma
37. Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
38. P015: Real World Escalated BEACOPDac Delivers Similar Outcomes to Escalated BEACOPP While Potentially Reducing Haematopoietic and Reproductive Toxicity
39. Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis
40. Actualités thérapeutiques dans le lymphome hodgkinien classique
41. Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related?
42. Lymphoma, Genito Urinary Tract
43. Unconventional immune-related phenomena observed using 18F-FDG PET/CT in Hodgkin lymphoma treated with anti PD-1 monoclonal antibodies
44. Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study
45. Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: Results from two independent cohorts
46. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte
47. Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.
48. Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma.
49. Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study.
50. Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.